It was a pleasure to meet with Prof. John Walton Sanders (Wake Forest School of Medicine and the Hefner VAMC, Winston-Salem, NC, USA) to discuss the a subset analysis of the Phase 3 FURI study investigating the outcomes of patients with Candida bone and joint infections when treated with ibrexafungerp.
The abstract entitled: ‘Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- What are the aims, and design of the FURI Phase III study and the subsequent subset analysis? (0:13)
- What are the eligibility criteria of the study? (1:16)
- What were the findings of the subset analysis investigating ibrexafungerp for Candida osteoarticular infections? (2:02)
- What will be the next steps towards regulatory approval of ibrexafungerp in this indication? (3:37)
Disclosures: John Sanders has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
